Literature DB >> 26361735

Synthesis of five and six-membered heterocycles bearing an arylpiperazinylalkyl side chain as orally active antinociceptive agents.

Claudia Vergelli1, Giovanna Ciciani1, Agostino Cilibrizzi2, Letizia Crocetti1, Lorenzo Di Cesare Mannelli3, Carla Ghelardini3, Gabriella Guerrini1, Antonella Iacovone1, Maria Paola Giovannoni4.   

Abstract

A number of heterocycles bearing an arylpiperazinylalkyl side chain and structurally related to the previously described lead ET1 (4-amino-6-methyl-2-[3-(4-p-tolylpiperazin-1-yl)propyl]-5-vinylpyridazin-3(2H)-one) was synthesized and tested for their antinociceptive activity in Writhing Test. Many compounds, tested at doses of 20-40 mg/kg po were able to reduce the number of abdominal constrictions by more than 47% and, in same cases, the potency is comparable to lead ET1 as for 5e, 24a, 27b and 27c. The analgesia induced by the active compounds was completely prevented by pretreatment with α2-antagonist yohimbine, confirming the involvement of the adrenergic system in the mechanism of action for these new compounds.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adrenergic system; Antinociception; Synthesis

Mesh:

Substances:

Year:  2015        PMID: 26361735     DOI: 10.1016/j.bmc.2015.08.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

Review 1.  Spinal α2 -adrenoceptors and neuropathic pain modulation; therapeutic target.

Authors:  Zahra Bahari; Gholam Hossein Meftahi
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

2.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.